Qiagen to Gain Array-Based Breast Cancer Test through Ipsogen Buy

Qiagen's planned acquisition of Ipsogen will provide the firm with a suite of CE-IVD marked PCR tests as well as an Affymetrix-manufactured microarray test that can be used to guide treatment for breast cancer patients.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.